Sanofi and Teva Pharmaceuticals reported positive new data from a Phase IIb trial of duvakitug, their co-developed inflammatory bowel disease (IBD) drug. The therapy prompted long-term clinical remission in patients with ulcerative colitis and Crohn’s disease.
Analysts see potential for duvakitug in the anti-TL1A class. Its high potency and selective characteristics could differentiate it from other anti-TL1A candidates in development.
Sanofi and Teva are advancing duvakitug into late-stage clinical trials.